In this project we will experimentally test and validate a PoC device based on our technology for the simultaneous measurement of three biomarkers (proteins MMP9, S100A6 and CST4) associated with the ophthalmological pathology of dry eye.
- RESEARCH TYPE Development of a biosensor technology
- RESEARCH YEAR 2018
This project intends to carry out a proof of concept of biod technology for its application to the detection of biomarkers related to Alzheimer's disease (TAU and beta-amyloid protein).
This project intends to carry out a proof of concept of biod technology for its application to the detection of biomarkers related to Alzheimer’s disease (TAU and beta-amyloid protein). To do this, we biofunctionalize the biosensor with a monolayer of the specific antibody of the biomarker to be detected, studying the most appropriate strategy for this bioapplication. A homogenous and stable biofunctionalization of the surface is key in the process. Once a protocol of optical biofunctionalization of the sensors has been achieved, they will be interrogated with our reading platform and, subsequently, the results will be compared with those resulting from applying other standard reference technologies, in order to check and “validate” experimentally biod technology for this application.
We will have the experience and know-how of the Center for Biomedical Technology of the UPM and, more specifically, the Laboratory of Optics, Photonics and Biophotonics, in the development of kits based on BICELLs adapted to these specific techniques. Part of the researchers that are part of this group of the CTB are authors of the aforementioned patents, so their advice and technical assistance will be crucial for the validation of the biokits and the reading device that we have developed.